Canada· CA-DIN-02245433

PIMOZIDE

A pimozide product containing pimozide, registered in Canada by AA PHARMA INC. The same ATC class is registered in 11 of our 19 countries.

ATC N05AG02

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedPIMOZIDEATCN05AG02REGISTER NO.CA-DIN-02245433PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Pimozide is registered in 11 of 19 countries.

Countries holding a registration under ATC N05AG02 (pimozide), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 6 of them publish a price we can compare per daily dose

Pimozide · ATC N05AG02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pimozide costs, country by country.

Normalised to the WHO defined daily dose (4 mg), the median price runs from $0.18 in France to $0.31 in Italy — a ×1.7 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Pimozide · price per daily dose (4 mg)

USD · FX 28 Sept 2026

  • IT Italy$0.31
  • FR France$0.18
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
PIMOZIDE
Manufacturer
AA PHARMA INC
Country
Canada (CA)
ATC code
N05AG02
ATC class
Pimozide
Defined daily dose
4 mg, O
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

317 interactions on record for pimozide.

Graded by severity as the source publishes them — 174 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pimozide · interactions on record

317 records

  • 174 severe
  • 140 moderate
  • 3 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pimozide in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pimozide products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

  • Belgium · Orap, Orap Forte
  • Germany · Orap, Orap Forte
  • Denmark · Orap
  • Spain · Orap, Orap Fuerte
  • France · Orap
  • United Kingdom (Northern Ireland) · Orap
  • Greece · Pirium
  • Italy · Orap
  • Luxembourg · Orap, Orap Forte
  • Malta · Orap
  • Netherlands · Orap
  • Portugal · Orap Forte

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/57409b21-63ea-4244-8a65-d1c04e3b5265
GET /v1/drugs/57409b21-63ea-4244-8a65-d1c04e3b5265?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02245433",
  "form": "TABLET",
  "class": "Human",
  "routes": [
    "ORAL"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "N05AG02",
  "schedule": [
    "Prescription"
  ],
  "drug_code": "69485",
  "strengths": [
    "4 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "PIMOZIDE"
  ],
  "product_categorization": null
}

See everything about pimozide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.